GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder With Comorbid Anxiety and Insomnia

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

August 31, 2028

Conditions
Major Depressive Disorder
Interventions
DRUG

Zelquistinel

Zelquistinel is a positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor

Trial Locations (1)

35294

University of Alabama at Birmingham, Birmingham

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Worldwide Clinical Trials

OTHER

lead

Syndeio Biosciences, Inc

INDUSTRY